BOLD
INSIDER BUYINSIDER SELLBoundless Bio, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeBoundless Bio is undergoing a reverse merger with Serapha Bio (expected close late 2026), effectively transitioning from an independent oncology company to a public shell for Serapha's pipeline. The company reported a significant Q2 2026 earnings miss (EPS of -$1.06 vs. estimate, 79% below consensus) with zero revenue, and has ceased enrollment in major trials (POTENTIATE) and discontinued diagnostic development ahead of the merger.
Red flags
- •Q2 2026 EPS missed consensus by 79.18% (-$1.06 actual vs. higher estimate)
- •Zero revenue reported in Q2 2026
- •Trailing twelve-month EPS of -$2.86 with net loss of -$64.01M
- •Ceased enrollment in POTENTIATE trial due to market and clinical considerations
- •Halted early cancer trial and discontinued ECHO diagnostic program
- •No further legacy drug development planned post-merger
- •Mixed-to-cautious analyst coverage (1-3 analysts; consensus ratings vary from 'Neutral' to 'Buy' but with low $4.00 price target suggesting limited upside)
- •Reverse merger structure creates execution risk and shareholder dilution concerns
Insider Activity
| Name | Title | Type | Shares | Price | Value | Filed | Src |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | — | SELL | 18K | $2.97 | $0.05M | 2026-08-26 | ↗ |
| TANG KEVIN | — | BUY | 3K | $2.44 | $0.01M | 2026-07-21 | ↗ |
| TANG KEVIN | — | BUY | 2K | $2.44 | $0.00M | 2026-07-20 | ↗ |
| TANG KEVIN | — | BUY | 265 | $2.44 | $0.00M | 2026-07-17 | ↗ |
| TANG KEVIN | — | BUY | 18K | $2.44 | $0.05M | 2026-07-16 | ↗ |
| TANG KEVIN | — | BUY | 2K | $2.44 | $0.00M | 2026-07-15 | ↗ |
| TANG KEVIN | — | BUY | 44K | $2.43 | $0.11M | 2026-07-14 | ↗ |
| TANG KEVIN | — | BUY | 48K | $2.42 | $0.12M | 2026-07-13 | ↗ |
| TANG KEVIN | — | BUY | 43K | $2.43 | $0.11M | 2026-07-10 | ↗ |
| TANG KEVIN | — | BUY | 7 | $2.48 | $0.00M | 2026-07-09 | ↗ |
| TANG KEVIN | — | BUY | 14K | $2.46 | $0.04M | 2026-07-08 | ↗ |
| TANG KEVIN | — | BUY | 16K | $2.48 | $0.04M | 2026-07-07 | ↗ |
| TANG KEVIN | — | BUY | 27K | $2.49 | $0.07M | 2026-07-06 | ↗ |
| TANG KEVIN | — | BUY | 10K | $2.49 | $0.02M | 2026-07-02 | ↗ |
| ARCH Venture Fund IX, L.P. | — | SELL | 16K | $2.49 | $0.04M | 2026-07-01 | ↗ |
| TANG KEVIN | — | BUY | 72K | $2.49 | $0.18M | 2026-07-01 | ↗ |
| CRANDELL KEITH | — | SELL | 16K | $2.49 | $0.04M | 2026-07-01 | ↗ |
| TANG KEVIN | — | BUY | 26K | $2.54 | $0.07M | 2026-06-30 | ↗ |
| TANG KEVIN | — | BUY | 100 | $2.50 | $0.00M | 2026-06-30 | ↗ |
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Citadel Advisors | SC 13G/A | — | 0.6% | -10.4% vs SPY -9.9% abs | 2026-08-14 | ↗ |